The IPC Virtual Psoriasis Masterclass is designed for early career dermatologists who are making treatment decisions and managing patients with psoriasis and are interested in specializing in psoriasis.
Over the five weekly two hours of the course, IPC’s world-renowned experts will cover various topics, including the pathogenesis of psoriasis, new and emerging therapies, and how to advocate for your patient.
The Masterclass agenda has been carefully developed to provide knowledge for daily use to the practicing dermatologist in an intimate environment designed to maximize faculty/participant interactions. Through lectures, panels, case-based discussions and question-answer sessions, attendees will obtain practical and important information for their clinical practice.
The IPC Masterclass is open to dermatologists who meet the following criteria:
There is no cost to attend the program, but space is limited. The application deadline is May 17, 2024.
Timezones:
16:00-18:00 BST
17:00-19:00 CEST
18:00-20:00 EEST
WELCOME + INTRODUCTION
Catherine Smith
Epidemiology: The Size of the Problem
Juul van den Reek
Clinical Phenotypes
Ulrich Mrowietz
Psoriasis Multi-Morbidity and Mechanisms
Ravi Ramessur
The Impact of Psoriasis
Matthias Augustin
Shared Decision Making to Address Patient and Clinical Goals
Christine Bundy
Q&A + CLOSING COMMENTS
Anna López Ferrer
WELCOME + INTRODUCTION
Anna López Ferrer
Genetic and Environmental Determinants of Disease: Relevance to Clinical Practice
Michael Simpson
Psoriasis: Assessment of Disease Severity in Clinical Practice
Lone Skov
Psoriatic Arthritis: Making the Diagnosis
Saakshi Khattri
Cardiometabolic Disease: How and When to Assess
José Carrascosa Carrillo
Q&A + CLOSING COMMENTS
Filip Rob
WELCOME + INTRODUCTION
Filip Rob
Lifestyle & Diet: What Do We Know
Jo Lambert
What’s New in Pustular Psoriasis
Jonathan Barker
Targeted Therapies: Where are the Differences?
Luigi Naldi
Topicals: When and How to Use
Robert Bissonnette
Q&A + CLOSING COMMENTS
Catherine Smith
WELCOME + INTRODUCTION
Catherine Smith
Psoriasis and Chronic Infections
Filip Rob
Psoriasis and Cancer
Ron Vender
Psoriasis and Conception, Pregnancy and Breast Feeding
Rick Woolf
Pediatric Psoriasis
Emmanuel Mahé
Q&A + CLOSING COMMENTS
Anna López Ferrer
WELCOME + INTRODUCTION
Anna López Ferrer
Future Therapies: What’s Coming Next
Anna López Ferrer
Precision Medicine and Predictors of Success
Satveer Mahil
Hot Cases – Presented by Delegates
Faculty Panel
Q&A + CLOSING COMMENTS
All Chairs
IPC Jr. Councilor Towhida Noor reviews the psoriasis pipeline: selective TYK2 inhibitors, long-acting IL-17 and IL-23 biologics, and IL-36 blockade in GPP.
IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.
PRE-ORDER YOUR COPY
In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.
IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.
